In the BALATON and COMINO trials, Vabysmo treatment resulted in early and sustained vision improvement. Credit: zehra soy from Pixabay.

Roche has reported positive data from the Phase III BALATON and COMINO clinical trials of Vabysmo (faricimab) to treat retinal vein occlusion (RVO).

The two double-masked, multicentre, randomised, international Phase III trials are designed to assess the safety and efficacy of Vabysmo against aflibercept.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The BALATON trial is being carried out in 553 branch retinal vein occlusion (BRVO) patients, and the COMINO trial in 729 central retinal or hemiretinal vein occlusion (CRVO) patients.

Findings from both trials demonstrated that the Vabysmo treatment resulted in early and sustained vision improvement.

Vabysmo also met the primary endpoint of non-inferior visual acuity gains compared to aflibercept treatment. Its safety profile was found to be consistent with the previous trials.

See Also:

The two trials demonstrated that more patients treated with Vabysmo had an absence of blood vessel leakage in the retina compared to patients treated with aflibercept in a pre-specified exploratory endpoint.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Roche chief medical officer and global product development head Levi Garraway said: “These encouraging results reinforce the potential of Vabysmo as a new treatment option for people experiencing vision loss associated with retinal vein occlusion.

“As these positive data continue to accrue, we believe Vabysmo may redefine the standard of care for multiple types of retinal conditions that can cause blindness.”

The company intends to submit the data from the BALATON and COMINO trials to health authorities worldwide, including European Medicines Agency and the US Food and Drug Administration (FDA), for approval to treat macular oedema caused due to RVO.

If approved, RVO will become the third indication for Vabysmo besides diabetic macular oedema and neovascular or ‘wet’ age-related macular degeneration.

Prior to this development, Roche reported positive data from the global Phase III COMMODORE 2 study of crovalimab in paroxysmal nocturnal haemoglobinuria (PNH) patients.